Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VRK1 | Q99986 | 15/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | TAF1 | P21675 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.33 |
| ▸ | VRK2 | Q86Y07 | 2/20 | 0.33 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.33 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17780301 | 0.95 | VRK1 (0.36) | VRK1BRD4TAF1LRRK2PARP1 | |
| SCHEMBL17780382 | 0.95 | VRK1 (0.36) | VRK1BRD4TAF1LRRK2PARP1 | |
| SCHEMBL17780448 | 0.93 | VRK1 (0.37) | VRK1BRD4LRRK2RPS6KA3VRK2 | |
| SCHEMBL17780596 | 0.93 | BRD4 (0.39) | VRK1BRD4TAF1PARP1 | |
| SCHEMBL17780556 | 0.93 | VRK1 (0.37) | VRK1BRD4TAF1LRRK2RPS6KA6 | |
| SCHEMBL17780559 | 0.93 | VRK1 (0.37) | VRK1BRD4TAF1LRRK2RPS6KA6 | |
| SCHEMBL17780337 | 0.93 | BRD4 (0.39) | VRK1BRD4TAF1PARP1 | |
| SCHEMBL17780591 | 0.93 | VRK1 (0.37) | VRK1BRD4TAF1LRRK2RPS6KA6 | |
| SCHEMBL17780536 | 0.91 | VRK1 (0.36) | VRK1BRD4TAF1LRRK2RPS6KA6 | |
| SCHEMBL17780445 | 0.91 | VRK1 (0.35) | VRK1BRD4TAF1RPS6KA3VRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9351974-B2 | Substituted pteridinones for the treatment of cancer | OSI Pharmaceuticals, LLC (US) | 2016-05-31 | — | — | US | claimed |
| US-9351974-B2 | Substituted pteridinones for the treatment of cancer | OSI Pharmaceuticals, LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351974-B2 | Substituted pteridinones for the treatment of cancer | OSI Pharmaceuticals, LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351974-B2 | Substituted pteridinones for the treatment of cancer | OSI Pharmaceuticals, LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140315911-A1 | DIHYDROPTERIDINONES | OSI Pharmaceuticals, LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140315911-A1 | DIHYDROPTERIDINONES | OSI Pharmaceuticals, LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140315911-A1 | DIHYDROPTERIDINONES | OSI Pharmaceuticals, LLC | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315911-A1 | DIHYDROPTERIDINONES | DHPS, DHODH, HYPK | VRK1 489/4885BRD4 3536/4885TAF1 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.